By Christopher Kuo

Insmed shares tumbled after the company reported higher operating expenses in its latest quarter.

Shares of the biopharmaceutical company fell 20% on Thursday to $109.19. The stock is down 37% year to date.

The company posted a loss of $163.6 million, or 76 cents a share, compared with a loss of $256.6 million, or $1.42 a share, a year earlier. Analysts polled by FactSet expected a loss of 96 cents a share.

Revenue rose to $306 million from $92.8 million a year earlier. Analysts expected revenue of $300.8 million.

The company's revenue from Arikayce treatment for lung disease rose 6% year over year. This was lower than analysts expected, according to Mizuho analysts. The company also reported lower Brinsupri new patient starts, the analysts said.

The company's operating expenses climbed. Selling, general and administrative expenses were $247.3 million, compared with $147.5 million a year earlier. Research and development expenses rose to $209.5 million from $152.6 million a year earlier.

Write to Christopher Kuo at chris.kuo@wsj.com

(END) Dow Jones Newswires

May 07, 2026 15:51 ET (19:51 GMT)

Copyright (c) 2026 Dow Jones & Company, Inc.